Alpine Immune Sciences, Inc.
ALPNN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jul 15, 2026
19wMarket Overview
Stock performance and key metrics
ALPN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Povetacicept | Phase 3 | Lupus Nephritis | - | - |
ALPN-101 | Phase 2 | Systemic Lupus Erythematosus | - | - |
Lupus Nephritis
1 drug in this indication
Systemic Lupus Erythematosus
1 drug in this indication
Immunoglobulin A Nephropathy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply